Zydus Cadila receives final approval for Cholestyramine for Oral Suspension USP

Zydus Cadila has received final approval to market Cholestyramine for Oral Suspension USP (Questran), 4 g resin per pouch or scoopful. It is used alongwith a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks. It will be manufactured at the group's formulations manufacturing facility at Baddi.

Powered by Capital Market - Live News